Meeting
2020 ASCO Virtual Scientific Program
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
Authors
Matthew P. Goetz
Mayo Clinic, Rochester, MN
Matthew P. Goetz , Erika Paige Hamilton , Mario Campone , Sara A. Hurvitz , Javier Cortes , Stephen R. D. Johnston , Guy Heinrich Maria Jerusalem , Hillary Graham , Hong Wang , Lacey Litchfield , Valerie Malyvanh Jansen , Miguel Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Clinical Trial Registration Number
NCT02246621, NCT02747004
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3519)
DOI
10.1200/JCO.2020.38.15_suppl.3519
Abstract #
3519
Poster Bd #
249
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2018 ASCO Annual Meeting
Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA).
First Author: Kabir Mody
Poster
2017 ASCO Annual Meeting
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
First Author: Lajos Pusztai